A5013064031- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Breast Lesions and Carcinomas
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Brain Metastases and Treatment
- Cancer Immunotherapy and Biomarkers
- Breast Implant and Reconstruction
- Radiopharmaceutical Chemistry and Applications
- Cancer Diagnosis and Treatment
- Cancer-related Molecular Pathways
- AI in cancer detection
- Cancer Risks and Factors
- Digital Radiography and Breast Imaging
- Chronic Lymphocytic Leukemia Research
- Chemokine receptors and signaling
- Lung Cancer Treatments and Mutations
- Cancer and Skin Lesions
- Estrogen and related hormone effects
- Immunotherapy and Immune Responses
- Multiple and Secondary Primary Cancers
- Neutropenia and Cancer Infections
- Medical Imaging Techniques and Applications
Tokyo Metropolitan Komagome Hospital
2014-2024
Breast Center
2020
Kindai University
2013
Saitama Medical University
2013
Saitama International Medical Center
2013
Nihon University
2011
Tokyo Medical and Dental University
2004-2008
Showa University
2006
Edogawa Hospital
2006
Abstract Therapeutic options for breast cancer patients with brain metastases (BM)/leptomeningeal carcinomatosis (LMC) are limited. Here, we report on the effectiveness and safety of trastuzumab deruxtecan (T-DXd) in human epidermal growth factor receptor 2-positive BM. Data were analyzed 104 administered T-DXd. Overall response rate (ORR), progression-free survival (PFS), overall (OS), intracranial (IC)-ORR, IC-PFS evaluated. ORR by investigator assessment was 55.7% (total population)....
Abstract We provide updated results (median follow-up duration: 20.4 months) of a retrospective study on the effectiveness trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer brain metastases (BM) and/or leptomeningeal disease (ROSET-BM). Median progression-free survival (PFS) was 14.6 months. overall (OS) not reached (NR); 24-month OS rate 56.0%. Subgroup analysis showed that median PFS 13.2 months analytical active BM,...
Abstract Background There is increasing interest in the use of liquid biopsies, but data on longitudinal analyses circulating tumor DNA (ctDNA) remain relatively limited. Here, we report a ctDNA analysis MONALEESASIA, phase Ib trial evaluating efficacy and safety ribociclib plus endocrine therapy (ET) Asian patients with hormone receptor–positive, human epidermal growth factor receptor-2–negative advanced breast cancer. Methods MONALEESASIA enrolled premenopausal postmenopausal Japanese...
Background Lynch syndrome (LS) patients have a high risk of developing various tumors. This study aimed to clarify the characteristics tumors in LS patients. Methods is retrospective review 55 treated at Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital. Results The median age diagnosis first malignant tumor LS-related was 44 (range, 19−65) 24−66) years, respectively. Of with tumors, 45 (93.8%) developed an as tumor. Colorectal cancer (CRC) 47 (85.4%), followed by...
Patients with advanced cancer undergo comprehensive genomic profiling in Japan only after treatment options have been exhausted. a very poor prognosis were not able to tests, resulting selection bias called length bias, which makes accurate survival analysis impossible. The actual impact of on the overall patients who undergone tests is unclear, yet appropriate methods for adjusting developed. To assess survival, we established simulation-based model adjustment. This study utilized...
Abstract Background: Brain metastases (BM) occur in 20%-50% of patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC), and their presence is a poor prognostic factor. Leptomeningeal carcinomatosis (LMC) occurs 12%–43% pts MBC. Therapeutic options for BC BM and/or LMC are limited. Results the DESTINY-Breast01 DESTINY-Breast03 studies have shown clinical benefit trastuzumab deruxtecan (T-DXd) HER2+ MBC stable BM; however, study populations were small did not include active...
Abstract Purpose To investigate clinical usefulness of eribulin-based neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) patients. Methods Patients group A (aged < 65 years with homologous recombination deficiency, HRD, score ≥ 42, or those at any age germline BRCA mutation, gBRCAm) were randomized to 4 cycles paclitaxel plus carboplatin (group A1) eribulin A2), followed by anthracycline. B HRD aged without 6 cyclophosphamide B1) capecitabine B2); non-responders the first...
Background: NK105 is a paclitaxel (PTX)-incorporating "core-shell-type" polymeric micellar nanoparticle formulation composed of block copolymers (polyethylene glycol and polyamino acid). The efficacy safety in advanced or recurrent breast cancer have never been compared at equivalent dose levels. Patients Methods: were randomly assigned to either PTX 1:1 ratio. study drug was administered on Day 1, 8, 15 28-day cycle with 80 mg/m 2 . primary endpoint overall response rate (ORR), secondary...
Abstract Purpose The randomized phase 2 Neo-peaks study examined usefulness of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 P) following docetaxel carboplatin (TCbHP) as compared with the standard TCbHP regimen. We previously reported that pCR rate after therapy tended to be higher followed by T-DM1 P. conducted an exploratory analysis prognosis 5 years surgery. Methods Neoadjuvant treatment (6 cycles; group A), (4 cycles) P B), and C, cycles in responders) were compared. Group C...
Due to the increase in number of early-stage breast cancer patients, there is growing interest minimally invasive local therapies for cancer. Radiofrequency ablation (RFA) therapy one most promising treatments. The Ablation Therapy Early Breast Cancer as Local (RAFAELO) study, a multicenter collaborative study that aims validate efficacy and safety RFA standardize its use cancer, was conducted under Advanced Medical Care B system 2013. This enrolled expected patients November 2017; moreover,...
Four clinical active surveillance trials including LORIS, COMET, LORD and LORETTA, are being conducted to assess whether women with low-risk ductal carcinoma in situ can safely avoid surgery. The present study aimed determine the rate of upstaging invasive cancer among patients a preoperative diagnosis evaluate incidence meeting eligibility criteria for four trials.The initially enrolled 180 183 calcifications who received by biopsy. Patients were classified as eligible according respective...
We aimed to confirm the efficacy and safety of oral histone deacetylase inhibitor entinostat in Japanese patients with hormone receptor-positive advanced/recurrent breast cancer explore potential biomarkers.This phase II, double-blind, randomized, placebo-controlled trial (ClinicalTrials.gov; NCT03291886) was conducted at 28 sites (September 2017-July 2020; interim analysis cutoff: April 2019). Patients progression/relapse following non-steroidal aromatase inhibitors were randomized 1:1 (5...
The prognosis of breast cancer-derived brain metastasis is poor, but new drugs and recent therapeutic strategies have helped extend survival in patients. Prediction responses outcomes not yet possible, however. In a retrospective study, we examined prognostic factors patients with metastasis, tested the utility cancer-specific Graded Prognostic Assessment these patients.Sixty-three diagnosed from cancer treated surgically adjuvantly were included. We clinical variables per primary tumor...
The ongoing, Phase Ib MONALEESASIA study is evaluating the efficacy and safety of ribociclib plus endocrine therapy in Asian patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Eligible from Japan, Hong Kong, Singapore were enrolled this 2-phase consisting a dose-escalation phase to determine maximum-tolerated dose recommended II letrozole, dose-expansion evaluate tolerability fulvestrant, or tamoxifen. An exploratory biomarker...
Sarcopenia is associated with postoperative complications in patients undergoing digestive surgery. In this study, we investigated the impact of preoperative sarcopenia on breast cancer who underwent total mastectomy. Patients mastectomy were included analysis. The relationship between presence and (e.g., skin flap necrosis seroma) incidence these as well surgical factors was investigated. Moreover, effects recurrence-free survival overall evaluated. psoas muscle index calculated using...